Company Modalis Therapeutics Corporation

Equities

4883

JP3922600006

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-07-16 am EDT			5-day change	1st Jan Change
70 ^JPY	0.00%		0.00%	-43.55%

Jul. 10	Modalis Therapeutics Partners Genixcure for Alzheimer's Treatment	MT
Jul. 10	Modalis and GENIXCURE Enter into Memorandum of Understanding for Research Collaboration to Develop Next-Generation Therapeutics	CI

Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.

Number of employees: 37

Managers	Title	Age	Since
Haru Morita FOU	Founder	54	15-12-31
Naoki Kobayashi DFI	Director of Finance/CFO	60	-
Tetsuya Yamagata CTO	Chief Tech/Sci/R&D Officer	-	-

Members of the board	Title	Age	Since
Joseph McCracken BRD	Director/Board Member	70	18-07-31
Toshio Furuta BRD	Director/Board Member	62	18-11-30
Haru Morita FOU	Founder	54	15-12-31
Teruhisa Tajima BRD	Director/Board Member	52	15-12-31
Hideki Takeda BRD	Director/Board Member	65	15-12-31
Osamu Nureki FOU	Founder	58	15-12-31
Miyuki Shimane BRD	Director/Board Member	70	18-11-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	40,875,830	34,765,167 ( 85.05 %)	63 ( 0.000154 %)	85.05 %

Name	Equities	%	Valuation
Haru Morita 15.49 %	6,026,300	15.49 %	3 M ¥
Osamu Nureki 5.826 %	2,266,100	5.826 %	986 116 ¥
Rheos Capital Works, Inc. (Investment Management) 3.586 %	1,395,000	3.586 %	607 048 ¥
SBI Investment Co., Ltd. 3.037 %	1,181,400	3.037 %	514 098 ¥
Yangu Kaihatsu KK 1.414 %	550,000	1.414 %	239 338 ¥
UTokyo Innovation Platform Co.,Ltd. 1.299 %	505,300	1.299 %	219 886 ¥
Fast Track Initiative, Inc. 1.217 %	473,400	1.217 %	206 005 ¥
Pegasus Tech Ventures, Inc. 0.9913 %	385,600	0.9913 %	167 798 ¥
Hideki Takeda 0.4969 %	193,300	0.4969 %	84 116 ¥
Teruhisa Tajima 0.2828 %	110,000	0.2828 %	47 868 ¥

Modalis Therapeutics Corp.

Y's Building, 4/F 16-5 Nihonbashikabutocho

103-0026, Tokyo

http://www.modalistx.com/jp/

address Modalis Therapeutics Corporation(4883)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MODALIS THERAPEUTICS CORPORATION	-43.55%	16.86M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	127B
REGENERON PHARMACEUTICALS, INC.	+24.61%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.72%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.20%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.81%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.58%	14.43B

Bio Therapeutic Drugs